Protective effect and localization by optical imaging of human renal CD133+ progenitor cells in an acute kidney injury model

Cristina Grange1, Aldo Moggio2, Marta Tapparo1, Stefano Porta2, Giovanni Camussi1 & Benedetta Bussolati2

1 Department of Medical Sciences, University of Torino, Torino, Italy
2 Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

Keywords
AKI, biodistribution, mesenchymal stem cells, renal progenitor cells, stem cells.

Correspondence
Benedetta Bussolati, Department of Molecular Biotechnology and Health Sciences, Centre for Molecular Biotechnology, University of Torino, via Nizza 52, 10126 Torino, Italy.
Tel: +39-011-6706453
Fax: +39-011-6631184
E-mail: benedetta.bussolati@unito.it

Funding Information
This work was supported by Regione Piemonte, PISTEM project.

Abstract
Recent approaches of regenerative medicine can offer a therapeutic option for patients undergoing acute kidney injury. In particular, mesenchymal stem cells were shown to ameliorate renal function and recovery after acute damage. We here evaluated the protective effect and localization of CD133+ renal progenitors from the human inner medulla in a model of glycerol-induced acute tubular damage and we compared the results with those obtained with bone marrow-derived mesenchymal stem cells. We found that CD133+ progenitor cells promoted the recovery of renal function, preventing tubular cell necrosis and stimulating resident cell proliferation and survival, similar to mesenchymal stem cells. In addition, by optical imaging analysis, CD133+ progenitor cells accumulated within the renal tissue, and a reduced entrapment in lung, spleen, and liver was observed. Mesenchymal stem cells were detectable at similar levels in the renal tissue, but a higher signal was present in extrarenal organs. Both cell types produced several cytokines/growth factors, suggesting that a combination of different mediators is involved in their biological action. These results indicate that human CD133+ progenitor cells are renotropic and able to improve renal regeneration in acute kidney injury.

Introduction
The intrinsic ability of tissue repair and regeneration necessary to regain functionality after ischemic, toxic, or inflammatory insults is limited in the mammalian kidney. Acute kidney injury (AKI) remains a major cause of in-hospital morbidity and mortality despite supply of supportive care, and possibly leads to chronic renal dysfunction (Goldstein et al. 2013). Recently, stem cell-based therapy appeared as a new strategy to support renal repair, being bone marrow-derived mesenchymal stem cells (MSCs) the most studied cell type and the most advanced in clinical development (Tögel et al. 2005). Injected bone marrow-derived MSCs are known to display a renoprotective effect in models of acute kidney injury mainly through paracrine mechanisms (Bi et al. 2007).

In parallel, different experimental studies showed the potential application of adult renal progenitors derived both from mouse or human renal tissue for the treatment of AKI (Bussolati et al. 2005; Dekel et al. 2006; Sagrinati et al. 2006; Kinomura et al. 2008; Langworthy et al. 2009; Ronconi et al. 2009; Lee et al. 2010). In humans, CD133+ cells, characterized by features of nondifferentiated renal
mesenchymal progenitors, were mainly identified in the Bowman capsule of glomeruli and in the proximal tubules (Bussolati et al. 2005; Sagrinati et al. 2006; Sallustio et al. 2010). These cortical CD133+ progenitor cells have been injected in murine models of glomerular toxicity and tubular necrosis (Bussolati et al. 2005; Sagrinati et al. 2006; Ronconi et al. 2009). In all experiments, injected CD133+ progenitors were detected into the renal injured tissue and were found to ameliorate renal function (Bussolati et al. 2005; Sagrinati et al. 2006; Ronconi et al. 2009). However, the localization of renal CD133+ cells in living animals and their biodistribution in the different organs has not yet been evaluated.

CD133+ progenitor cells were also detected in the inner medullary papilla region, being localized in the Henle’s loop and in the S3 limb segments (Ward et al. 2011; Bussolati et al. 2012). CD133+ cells isolated from the renal medulla were shown to possess higher differentiative ability and stemness markers with respect to those in proximal tubules, possibly due to the maintenance of stem features in the hypoxic environment of the inner medulla (Bussolati et al. 2012). Therefore, it could be of interest to evaluate the in vivo effect and localization of these cells from stroma and aggregates. The filtrate was pelleted by centrifugation. CD133+ cells were isolated from bone marrow and labeled with DiD (Ex: 640 nm; Em: 700 nm), by magnetic cell sorting, using the MACS system (Miltenyi Biotec, Bergisch Gladbach, Germany), and cells resuspended in expansion medium (EBM medium plus supplement kit; Lonza, Basel, Switzerland) without serum addition at a density of $1 \times 10^5$ viable cells per cm$^2$. Cell lines, obtained from different renal specimens were used between passage 2 and 5. Bone marrow-derived MSCs were obtained from Lonza, cultured and characterized as previously described (Herrera et al. 2007; Bruno et al. 2009). Briefly, the MSCs were cultured in the presence of Mesenchymal Stem Cells Basal Medium (MSCBM, Lonza). All cell preparations at different passages of culture expressed the typical MSC markers: CD105, CD73, CD44, CD90, CD166, and CD146 and not hematopoietic markers like CD45, CD14, and CD34, evaluated by cytofluorimetric assay (Table 1). The adipogenic, osteogenic, and chondrogenic differentiation ability of MSCs was determined as previously described (Herrera et al. 2007).

Cells were labeled with DiD (Ex: 640 nm; Em: 700 nm) (Molecular Probes, Life Technology, NY) solution without serum for 20 min at 37°C (Garrovo et al. 2013; Herrera et al. 2013). Cells were then washed in complete medium by centrifugation and cultivated for 24 h before injection in vivo. Cells were counted and viability tested by the trypan blue exclusion assay (Sigma).

### Materials and Methods

#### Cells and labeling procedure

Renal CD133+ progenitor cells were obtained from the normal portion of the papillary region of the inner medulla obtained from surgically removed kidneys (Bussolati et al. 2012), after approval of the Ethical Committee for the use of human tissue of the Department of Medical Sciences of the University of Torino. Briefly, tissue samples of approximately 3–5 mm$^3$ were obtained at the papillary region of a renal pyramid. Tissue was rinsed with Hank’s Balanced Salt Solution (Sigma, St. Louis, MO) and, after cutting, digested in 0.1% Collagenase type I (Sigma) for 45 min at 37°C. Tissue was subsequently forced through a graded series of meshes to separate the cell components from stroma and aggregates. The filtrate was pelleted by centrifugation. CD133+ cells were isolated from bone marrow and labeled with DiD (Ex: 640 nm; Em: 700 nm), by magnetic cell sorting, using the MACS system (Miltenyi Biotec, Bergisch Gladbach, Germany), and cells resuspended in expansion medium (EBM medium plus supplement kit; Lonza, Basel, Switzerland) without serum addition at a density of $1 \times 10^5$ viable cells per cm$^2$. Cell lines, obtained from different renal specimens were used between passage 2 and 5. Bone marrow-derived MSCs were obtained from Lonza, cultured and characterized as previously described (Herrera et al. 2007; Bruno et al. 2009). Briefly, the MSCs were cultured in the presence of Mesenchymal Stem Cells Basal Medium (MSCBM, Lonza). All cell preparations at different passages of culture expressed the typical MSC markers: CD105, CD73, CD44, CD90, CD166, and CD146 and not hematopoietic markers like CD45, CD14, and CD34, evaluated by cytofluorimetric assay (Table 1). The adipogenic, osteogenic, and chondrogenic differentiation ability of MSCs was determined as previously described (Herrera et al. 2007). Cells were labeled with DiD (Ex: 640 nm; Em: 700 nm) (Molecular Probes, Life Technology, NY) solution without serum for 20 min at 37°C (Garrovo et al. 2013; Herrera et al. 2013). Cells were then washed in complete medium by centrifugation and cultivated for 24 h before injection in vivo. Cells were counted and viability tested by the trypan blue exclusion assay (Sigma).

| Table 1. Phenotypic characteristics of CD133+ cells and MSCs. |
|---------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cell preparations | CD133 | CD24 | CD73 | CD105 | CD44 | CD73 | CD29 | Vimentin | Pax2 |
| CD133+ cells | 97.5 | 84.9 | 95.5 | 6.4 | 96.2 | 71.3 | 81.9 | >95 | >95 |
| MSCs | 0 | 0 | 97.3 | 73.0 | 91.3 | 89.3 | 88.1 | >95 | 0 |

The expression of the renal progenitor markers CD133 and Pax2 and of the mesenchymal markers CD73, CD105, CD44, CD29, and vimentin by the cell isolates used in the study was evaluated by cytofluorimetric analysis or immunofluorescence staining, as described (Bruno et al. 2009; Goldstein et al. 2013). Cells were tested between the second and the third culture passage. Data are expressed as % positive cells and are mean of four different cell lines for CD133+ cells and of three different cell lines for MSCs.
were treated with labeled CD133+ progenitors (fluorescence. Twenty-four hours after AKI damage, mice
Mucedola, Settimo Milanese, Italy) to reduce tissue auto-
Mice were fed for 1 week with a special diet (AIN 79, 
tions every day. For biodistribution experiments, male
animals were monitored for activity and physical condi-
tion number: 1.3.10). Mice were kept in our institutional
animal facility under well-controlled conditions of
temperature, humidity with access to food and water ad
libitum. AKI was induced in SCID mice (Charles River
Laboratories, Lyon, France) by i.m. injection of 7.5 mL/kg
glycerol (Sigma). Mice received 5 × 10^5 CD133+ progeni-
tors or MSCs in 150 µL PBS or an equal volume of PBS
as control (n = 6 mice/group for each experimental
point) 24 h after the glycerol injection. Mice were sacri-
ficed at different times after cell or vehicle administra-
tions, and kidneys and samples for blood urea nitrogen
(BUN) and creatinine determination were collected. The
animals were monitored for activity and physical condi-
tions every day. For biodistribution experiments, male
CD1 nude mice were used (Charles River Laboratories).
Mice were fed for 1 week with a special diet (AIN 79,
Mucedola, Settimo Milanese, Italy) to reduce tissue auto-
fluorescence. Twenty-four hours after AKI damage, mice
were treated with labeled CD133+ progenitors (n = 8) or
MSCs (n = 6) or PBS (n = 8) and sacrificed 48 h after.

Glycerol-induced model of AKI

Animal studies were conducted in accordance with the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals. The protocol was approved by the
Committee of Bioethics of the University of Torino (Per-
mit Number: 1.3.10). Mice were kept in our institutional
animal facility under well-controlled conditions of
temperature, humidity with access to food and water ad
libitum. AKI was induced in SCID mice (Charles River
Laboratories, Lyon, France) by i.m. injection of 7.5 mL/kg
glycerol (Sigma). Mice received 5 × 10^5 CD133+ progeni-
tors or MSCs in 150 µL PBS or an equal volume of PBS
as control (n = 6 mice/group for each experimental
point) 24 h after the glycerol injection. Mice were sacri-
ficed at different times after cell or vehicle administra-
tions, and kidneys and samples for blood urea nitrogen
(BUN) and creatinine determination were collected. The
animals were monitored for activity and physical condi-
tions every day. For biodistribution experiments, male
CD1 nude mice were used (Charles River Laboratories).
Mice were fed for 1 week with a special diet (AIN 79,
Mucedola, Settimo Milanese, Italy) to reduce tissue auto-
fluorescence. Twenty-four hours after AKI damage, mice
were treated with labeled CD133+ progenitors (n = 8) or
MSCs (n = 6) or PBS (n = 8) and sacrificed 48 h after.

Renal function

Blood samples for measurement of BUN and plasma cre-
atinine were collected 0, 1, 3, 5, and 8 days after glycerol
treatment. Serum creatinine was measured using a colori-
metric microplate assay based on the Jaffé reaction
(QuantiChrom Creatinine Assay, BioAssay Systems,
Hayward, CA). BUN was measured by direct quantifica-
tion of serum urea with a colorimetric assay kit according
to the instruction protocol (QuantiChrom Urea Assay,
BioAssay Systems).

Morphological studies

For renal histology, 5 µm-thick paraffin kidney sections
were routinely stained with hematoxylin and eosin. Luminal
hyaline casts and cell lose (denudation of tubular base-
ment membrane) were assessed in nonoverlapping fields
(up to 10 for each section) using a 40 x objective (high-
power field, HPF). Number of casts and tubular profiles
showing necrosis were recorded in a single-blind fashion
(Bruno et al. 2009). Immunohistochemistry for the detec-
tion of proliferation of tubular cells was performed as pre-
viously described (Bruno et al. 2009). Briefly, kidney
sections were subjected to antigen retrieval, and slides were
blocked and labelled with 1:400 of monoclonal anti-PCNA
(Santa Cruz Biotechnology, Santa Cruz, CA). Immunoperox-
odase staining was performed using 1:300 dilution of
anti-mouse HRP (Pierce, Rockford, IL). Scoring for
PCNA-positive cells was carried out by counting the number
of positive nuclei per field in 10 randomly chosen sec-
tions of kidney cortex using 40 x magnification.

Apoptosis was performed by TUNEL assay (Millipore,
Vimodrone, MI) on slices of kidneys recovered after 48 h
post cell injection (day 3), following the manufacturer’s
instruction. The number of apoptotic cells per field in 10
randomly chosen sections, using 200 x magnification, was
counted and expressed as mean ± SD.

Confocal microscopy analysis was performed on frozen
sections for the detection of HLA-class I, of Ki67 prolifera-
tion marker, and of pan cytokeratin. Sections were
labelled with mouse anti-HLA and rabbit polyclonal anti-
Ki67 antibodies (both from Abcam, Cambridge Science
Park, UK) or with rabbit anti-HLA (Santa Cruz) and
mouse anti-pan cytokeratin (Biolegend, San Diego, CA)
or rat anti-CD31 (Abcam). Alexa Fluor anti-rabbit or
anti-mouse or anti-rat antibodies (Molecular Probes, Lei-
den, the Netherlands) were used as secondary antibodies.
Confocal microscopy analysis was performed using a Zeiss
LSM 5 Pascal Model Confocal Microscope (Carl Zeiss
International, Germany). Hoechst 33342 dye (Sigma) was
added for nuclear staining. HLA-positive cells were
counted in 10 randomly chosen sections, using 400 x
magnification, and expressed as mean ± SD.

Cytokine assay

To measure the cytokines produced by CD133+ cells and
by MSCs, we performed a multiplex cytokine array based
on fluorescently dyed microspheres (Bio-Plex, Biorad,
Hercules, CA). CD133+ cells and MSCs were cultured to
a confluence of 90%. Cells were then cultured for 12 h in DMEM (Lonza) with 0.5% albumin (Sigma) and supernatant (conditioned medium) collected and frozen at −20°C after centrifugation (1200 rpm, 4°C, 5 min) to remove cellular debris. The cytokine assay was performed for three different isolated cells of CD133+ cells and MSCs.

**Statistical analysis**

Results are generally expressed as mean ± SD. Statistical analysis was performed by ANOVA with Dunnett’s multicomparison test. A P-value of <0.05 was considered significant.

**Results**

**Effect of CD133+ cells on the recovery of glycerol-induced AKI and comparison with MSCs**

CD133+ cells isolated from the human renal inner medulla were previously described to display progenitor phenotype and properties (Bussolati et al. 2012, 2013).
CD133+ cells expressed several markers in common with MSCs (CD73, CD29, CD44, and vimentin, but not CD105) and, at variance of MSCs, the renal embryonic marker PAX2, indicating their renal origin (Table 1). To investigate the therapeutic effect of CD133+ cells derived from the human inner medulla, experimental AKI was induced in SCID mice by glycerol injection, as described before (Bussolati et al. 2005; Bruno et al. 2009). Intramuscular injection of glycerol causes rhabdomyolyses of the muscular tissue, thereby releasing large quantities of enzymes, myoglobin, and iron and causing renal tubular injury. After the glycerol injection, serum creatinine and BUN levels increased as soon as after 24 h, and remained elevated over the course of 5 days to normalize thereafter. One day after the induction of AKI, mice received $5 \times 10^5$ CD133+ cells or MSCs intravenously via the tail vein. Control animals received only PBS. Mice injected with CD133+ cells exhibited a rapid amelioration of the renal function, as evaluated by BUN and creatinine levels (Fig. 1A and B). In particular, a significant reduction in BUN and creatinine was observed at day 3 (48 h after treatment) and 5 with respect to that in animals treated with PBS alone. We next compared the effect of CD133+ cells with that of MSCs. As expected, MSCs rapidly protected against the development of AKI. The levels of BUN were lower in animals treated with MSCs with respect to CD133+ cells, whereas no difference was observed in creatinine levels (Fig. 1A and B).

**CD133+ cells and MSCs inhibited tubular necrosis and enhanced cell proliferation**

On day 3 after injury, the histological evaluation of the renal tissue of glycerol-injected mice showed diffuse epithelial damage characterized by necrosis and vacuolization of tubular epithelial cells. In addition, proximal tubular cells showed loss of brush border and intratubular protein casts (Fig. 1C). Animals treated with CD133+ cells or MSCs exhibited reduced tissue damage compared to PBS-treated control animals as soon as at day 3 after glycerol injection (48 h after stem cell injection) (Fig. 1C). As assessed by morphometric evaluation of injury, stem..
cell-injected animals had a significantly lower number of cast containing tubules and a lower number of necrotic tubules compared to PBS-treated animals with AKI (Fig. 1D and E). Moreover, mice that received CD133\(^+\) or MSCs showed a significant reduction in apoptotic tubular cells compared with animals treated with PBS, as detected by TUNEL assay (Fig. 2A and B). No significant difference was observed between animals treated with CD133\(^+\) cells or MSCs.

We next evaluated the proliferation of proximal tubular cells in animals with AKI as a parameter of renal regenerative response. Treatment with CD133\(^+\) cells as well as with MSCs induced a significantly higher proliferation of tubular cells with respect to PBS-treated controls at day 3 after injury (Fig. 2C and D).

### Intravenously-injected CD133\(^+\) cells and MSCs localized in the kidney of AKI mice

The cell accumulation within the kidney was assessed by IVIS using CD133\(^+\) cells or MSCs labelled with DiD dye. A linear relation between cell number and fluorescence intensity was observed on labeled cells in vitro and a small number of cells, as low as \(5 \times 10^3\), was detectable. Equal number of CD133\(^+\) cells or MSCs generated comparable signals (Fig. 3A). Localization of the labeled cells was observed in whole body images and in ex vivo isolated organs at 48 h after the injection (day 3) (Figs. 3 and 4). As shown in Figure 3B and C, 48 h after intravenous injection CD133\(^+\) cells were detectable in the kidney with AKI damage. The fluorescence signal was higher than that of PBS-treated animals and clearly detectable in the kidney region although lower than that obtained with labeled MSCs (Fig. 3B and C).

The analysis of isolated organs revealed a high localization of CD133\(^+\) cells within the kidney similar to that of MSCs (Fig. 4A and B). At variance, the localization within spleen and liver was significantly higher for MSCs than for CD133\(^+\) cells (Fig. 4C). Accumulation in lung was similar for the two cell types (Fig. 4C).

Immunofluorescence staining performed using human HLA Class I confirmed the engraftment of CD133\(^+\) cells and MSCs cells within the renal tissue after 48 h (Fig. 5). Cells were mainly present in renal interstitial tissue, but some CD133\(^+\) cells or MSCs were also detectable within glomeruli or tubular structures. No difference in cell number (12.9 ± 7.2 CD133\(^+\) cells; 13.4 ± 6.2 MSCs) or localization was detectable between the two stem cell types.

![Figure 3](image-url)

**Figure 3.** Localization of labeled stem cells in vivo by IVIS. (A) Representative fluorescence images of increasing number of DiD-labeled stem cells (from \(2.5 \times 10^4\) to \(500 \times 10^3\)) in an equal volume of 100 \(\mu\)L PBS evaluated in vitro. (B) Representative fluorescence images of mice with AKI injected with DiD-labeled stem cells or PBS evaluated at day 3 after damage. (C) Quantification of fluorescence intensity of the kidney region, calculated in ROI, expressed as the mean of average radiance ± SD of mice injected with labelled CD133\(^+\) cells or MSCs or PBS. Eight nude mice injected with PBS or CD133\(^+\) cells and six with MSCs were evaluated. ANOVA with Dunnett’s multicomparison test was performed: *\(P < 0.05\) stem cells versus PBS.
sources. Colocalization studies with cytokeratin and CD31 showed absence of differentiation into epithelial or endothelial cells at this time point. In addition, double staining with Ki67 and HLA Class I showed that the majority of human cells were not in a proliferative phase (Fig. 5B).

**Comparison of grow factors and cytokines produced by cultured CD133+ cells and MSCs**

To investigate the possible mechanisms of repair induced by CD133+ cells and MSCs, we investigated the secretion of cytokines involved in tissue repair by a multiplex cytokine assay (Fig. 6). Both cell types released high levels of vascular endothelial growth factor. The main difference in cytokine/growth factors produced by CD133+ cells and MSCs was a preferential release of platelet-derived growth factor, fibroblast growth factor, leukemia inhibitory factor, and tumor necrosis factor α by CD133+ cells with respect to MSCs. In addition, IL-15, a kidney-specific factor involved in renal differentiation (Giron-Michel et al. 2013), was selectively released by CD133+ cells. At variance, MSCs showed a selective release of hepatocyte growth factor, known to be involved in epithelial cell regeneration (Matsumoto and Nakamura 2001).

**Discussion**

In the present study, we investigated the potential of renal progenitor cell therapy in murine experimental AKI. We demonstrated that CD133+ progenitor cells isolated from the human renal inner medulla accelerate the recovery of AKI, similar to MSCs, prevented tubular cell necrosis and promoted cell proliferation. In addition, CD133+ progenitor cells were detectable by optical imaging within the renal tissue, with low entrapment in extrarenal organs.

Several experimental evidences indicate that administration of cells with stem/progenitor properties is effective in preventing renal damage and promoting its recovery after an ischemic or toxic insult. In this setting, MSCs from bone marrow or from fat and neonatal birth-associated tissues (umbilical cord, placenta, and amniotic fluid) were proved to be successful (Aggarwal et al. 2013; Casiraghi et al. 2013).

A possible additional benefit in the exploitation of the regenerative properties of MSCs may derive from the use of tissue-specific cells. Indeed, the gene expression profile comparative analysis of murine MSCs derived from kidney and bone marrow showed that renal MSCs express a selected pattern of genes possibly related to a memory of
tissue origin (Pelekanos et al. 2012). This suggests that renal MSCs exhibit organ-specific characteristics that could provide an advantage with respect to MSCs from unrelated organs. Cells with mesenchymal features and progenitor properties have been detected by mean of CD133 expression within different segments of the nephron (Bussolati et al. 2005, 2012; Sagrinati et al. 2006; Sallustio et al. 2010; Smeets et al. 2013). The physiological involvement of resident CD133+ progenitors in tissue regeneration after injury has been indicated by studies showing the increase and proliferation of these cells in renal transplanted kidneys undergoing ischemic damage and in biopsies of AKI patients (Loverre et al. 2008; Smeets et al. 2013). In addition, administration of CD133+ cells from tubules was reported to promote repair in AKI models, mainly by engraftment within murine tubules (Bussolati et al. 2005). Recently, a population of CD133+ cells has been detected in the renal medulla (Ward et al. 2011; Bussolati et al. 2012). We here show that CD133+ cells isolated from the human inner medulla and expanded in vitro promoted the recovery of renal function in a glycerol model of AKI. Moreover, CD133+ cells ameliorated the morphological features of the injured kidneys, reducing tubular necrosis and casts and promoting tubular cell proliferation and survival.

The effects observed after CD133+ cell infusion in terms of renal function were comparable to those of bone marrow-derived MSCs, as reported previously (Herrera et al. 2004, 2007; Imberti et al. 2007; Morigi et al. 2008). At variance, we observed a clearly different biodistribution of the injected cells. Cells have been tracked using fluorescence methods with NIR dyes, such as the DiD dye, that provide efficient cell labeling without toxicity with a stable and strong signal. The use of small-molecule fluorophores and, in particular, NIR molecules is a powerful tool to track stem cells for noninvasive visualization, giving the possibility to follow and to localize labeled cells in living whole-body animal. These dyes were employed for in vivo cell, antibody, and extracellular vesicle detection (Zou et al. 2009; Boddington et al. 2011; Hood et al. 2011). Using optical imaging, previous experiments showed the possibility to localize and compare the distribution of MSCs in the kidney and other organs of AKI animals after intravenous or intra-arterial injection (Tögel et al. 2008). We here confirmed using optical imaging that after injection in the tail vein, MSCs distributed in several organs, including kidney, lung, liver, and spleen. At variance CD133+ cells showed a high renal localization, but a reduced entrapment in lung, liver, and spleen.

It has been reported that paracrine factors released from MSCs localized in distant sites could be sufficient for their beneficial effects (Zhuo et al. 2013). In addition, as during AKI other organs such as the lung can be injured (Ahuja et al. 2012), the nonspecific homing of the injected cells might also contribute to systemic tissue repair. Nevertheless, the localization of the administered cells in the kidney might be more effective to obtain the desired therapeutic properties even when paracrine mechanisms are involved. In fact, within injured tissues, cells are exposed to an advantageous inflammatory environment that may influence their behavior leading to a bidirectional effect, from cells to the tissue and backward (Del Tatto et al. 2011).
Previous studies showed the integration of CD133+ cells isolated from cortex within murine renal structures as well as their proliferation (Bussolati et al. 2005; Angelotti et al. 2012). We here found that CD133+ cells, observed at an early time (48 h after their injection), were mainly localized in the interstitium and few cells were also detectable within renal tubular or glomerular structures. However, we only found a limited proliferation of CD133+ cells from the inner medulla, possibly indicating the involvement of paracrine mechanisms, as already described for MSCs (Imberti et al. 2007; Bruno et al. 2009; Gatti et al. 2011). This is also suggested by the lack of acquirement of epithelial or endothelial markers. Although further studies are required to analyze the possible integration of CD133+ cells from inner medulla in the murine kidney and their differentiation at later time, these results may suggest that these cells display differential properties with respect to those from cortex, as previously described (Bussolati et al. 2012). Indeed, CD133+ cells from the inner medulla were shown in vitro to be responsible for erythropoietin production (Bussolati et al. 2013). In the context of AKI, erythropoietin may play tissue-specific roles unrelated to erythropoiesis such as modulation of angiogenesis and cell survival (Bahlmann and Fliser 2009; Wenger and Hoogewijs 2010). Moreover, several other factors released by CD133+ cells are considered of great importance in the modulation of renal regeneration. In particular, IL-15 is a survival factor for tubular cells, involved in the maintenance of the renal epithelial phenotype (Giron-Michel et al. 2013).

In conclusion, our results suggest that human isolated CD133+ renal progenitors could be suitable for cell therapy in acute tubular damage. In addition, these cells showed characteristics that might be related to their renal origin, such as their high renal localization and the production of renoprotective factors that could be exploited for renal regeneration. The possible clinical application of CD133+, both from cortex and medulla, might be limited by the availability of the organ source in comparison to multiple sources available for MSCs. However, the knowledge of the function of human CD133+ cells could lead to new pharmacological approaches targeting renal progenitors.

Acknowledgments
We thank Claudia Cavallari for her technical support.

Conflict of Interest
None declared.

References
Aggarwal, S., A. Moggio, and B. Bussolati. 2013. Concise Review: Stem/progenitor cells for renal tissue repair: current knowledge and perspectives. Stem Cells Transl. Med. 2:1011–1019.
Ahuja, N., A. Andres-Hernando, C. Altmann, R. Bhargava, J. Bacalja, R. G. Webb, et al. 2012. Circulating IL-6 mediates lung injury via CXCL1 production after acute kidney injury in mice. Am. J. Physiol. Renal Physiol. 303:F864–F872.
Angelotti, M. L., E. Ronconi, L. Ballerini, A. Peired, B. Mazzinghi, C. Sagrinati, et al. 2012. Characterization of renal progenitors committed toward tubular lineage and...
their regenerative potential in renal tubular injury. Stem Cells 30:1714–1725.

Bahlmann, F. H., and D. Fliser. 2009. Erythropoietin and renoprotection. Curr. Opin. Nephrol. Hypertens. 18:15–20.

Bi, B., R. Schmitt, M. Israilova, H. Nishio, and L. G. Cantley. 2007. Stromal cells protect against acute tubular injury via an endothocrine effect. J. Am. Soc. Nephrol. 18:2486–2496.

Boddington, S. E., E. J. Sutton, T. D. Henning, A. J. Nedopil, B. Sennino, A. Kim, et al. 2011. Labeling human mesenchymal stem cells with fluorescent contrast agents: the biological impact. Mol. Imaging Biol. 13:3–9.

Bruno, S., C. Grange, M. C. Deregibus, R. A. Calogero, S. Saviozzi, F. Collino, et al. 2009. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J. Am. Soc. Nephrol. 20:1053–1067.

Bussolati, B., S. Bruno, C. Grange, S. Buttiglieri, M. C. Deregibus, D. Cantino, et al. 2005. Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 166:545–555.

Bussolati, B., A. Moggio, F. Collino, G. Aghemo, G. D’Armento, C. Grange, et al. 2012. Hypoxia modulates the undifferentiated phenotype of human renal inner medullary CD133+/progenitors through Oct4/miR-145 balance. Am. J. Physiol. Renal. Physiol. 302:116–128.

Bussolati, B., C. Lauritano, A. Moggio, F. Collino, M. Mazzone, and G. Camussi. 2013. Renal CD133+/CD73+ progenitors produce erythropoietin under hypoxia and prolyl hydroxylase inhibition. J. Am. Soc. Nephrol. 24:1234–1241.

Casiraghi, F., N. Perico, and G. Remuzzi. 2013. Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr. Opin. Organ Transplant. 18:51–58.

Dekel, B., L. Zangi, E. Shezen, S. Reich-Zeliger, S. Eventov-Friedman, H. Katchman, et al. 2006. Isolation and characterization of nontubular sca-1+lin-multipotent stem/progenitor cells from adult mouse kidney. J. Am. Soc. Nephrol. 17:3300–3314.

Del Tatro, M., T. Ng, J. M. Aliotta, G. A. Colvin, M. S. Dooner, D. Berz, et al. 2011. Marrow cell genetic phenotype change induced by human lung cancer cells. Exp. Hematol. 39:1072–1080.

Garrovo, C., N. Bergamin, D. Bates, D. Ceselli, A. P. Beltrami, A. Lorenzon, et al. 2013. In vivo tracking of murine adipose tissue-derived multipotent adult stem cells and ex vivo cross-validation. Int. J. Mol. Imaging 2013:42961.

Gatti, S., S. Bruno, M. C. Deregibus, A. Sordi, V. Cantaluppi, C. Tetta, et al. 2011. Microvesicles derived from human adult mesenchymal stem cells protect against ischemia-reperfusion-induced acute and chronic kidney injury. Nephrol. Dial. Transplant. 26:1474–1483.

Giron-Michel, J., S. Azzi, S. Ferrini, S. Chouaib, G. Camussi, P. Eid, et al. 2013. Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis. Cytokine Growth Factor Rev. 24:13–22.

Goldstein, S. L., B. L. Jaber, S. Faubel, and L. S. Chawla. 2013. Acute Kidney Injury Advisory Group of American Society of Nephrology. AKI transition of care: a potential opportunity to detect and prevent CKD. Clin. J. Am. Soc. Nephrol. 8:476–483.

Herrera, M. B., B. Bussolati, S. Bruno, V. Fonsato, G. M. Romanuzzi, and G. Camussi. 2004. Mesenchymal stem cells contribute to the repair of acute tubular epithelial injury. Int. J. Mol. Med. 14:1035–1041.

Herrera, M. B., B. Bussolati, S. Bruno, L. Morando, G. Mauriello-Romanazzi, F. Sanavio, et al. 2007. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 72:430–441.

Hood, J. L., R. S. San, and S. A. Wickline. 2011. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71:3792–3801.

Imberti, B., M. Morigi, S. Tomasoni, C. Rota, D. Corna, L. Longaretti, et al. 2007. Insulin-like growth factor–I sustains stem cell mediated renal repair. J. Am. Soc. Nephrol. 18:2921–2928.

Kinomura, M., S. Kitamura, K. Tanabe, K. Ichinose, K. Hirokoshi, Y. Takazawa, et al. 2008. Amelioration of cisplatin-induced acute renal injury by renal progenitor-like cells derived from the adult rat kidney. Cell Transplant. 17:143–158.

Langworthy, M., B. Zhou, M. de Caestecker, G. Moecckel, and H. S. Baldwin. 2009. NFATc1 identifies a population of proximal tubule cell progenitors. J. Am. Soc. Nephrol. 20:311–321.

Lee, P. T., H. H. Lin, S. T. Jiang, P. J. Lu, K. J. Chou, H. C. Fang, et al. 2010. Mouse kidney progenitor cells accelerate renal regeneration and prolong survival after ischemic injury. Stem Cells 28:573–584.

Loverre, A., C. Capobianco, P. Ditonno, M. Battaglia, G. Grandaliano, and F. P. Schena. 2008. Increase of proliferating renal progenitor cells in acute tubular necrosis underlying delayed graft function. Transplantation 85:1112–1119.

Matsumoto, K., and T. Nakamura. 2001. Hepatocyte growth factor: renotrophic role and potential therapeutics for renal diseases. Kidney Int. 59:2023–2038.

Morigi, M., M. Introna, B. Imberti, D. Corna, M. Abbate, C. Rota, et al. 2008. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 26:2075–2082.

Pelekanos, R. A., J. Li, M. Gongora, V. Chandrakanthan, J. Scown, N. Suhami, et al. 2012. Comprehensive transcriptome and immunophenotype analysis of renal and cardiac MSC-like populations supports strong congruence...
with bone marrow MSC despite maintenance of distinct identities. Stem Cell Res. 8:58–73.
Ronconi, E., C. Sagrinati, M. L. Angelotti, E. Lazzeri, B. Mazzinghi, L. Ballerini, et al. 2009. Regeneration of glomerular podocytes by human renal progenitors. J. Am. Soc. Nephrol. 20:322–332.
Sagrinati, C., G. S. Netti, B. Mazzinghi, E. Lazzeri, F. Liotta, F. Frosali, et al. 2006. Isolation and characterization of multipotent progenitor cells from the Bowman’s capsule of adult human kidneys. J. Am. Soc. Nephrol. 17:2443–2456.
Sallustio, F., L. De Benedictis, G. Castellano, G. Zaza, A. Loverre, V. Costantino, et al. 2010. TLR2 plays a role in the activation of human resident renal stem/progenitor cells. Faseb J. 24:514–525.
Smeets, B., P. Boor, H. Dijkman, S. V. Sharma, P. Jirak, F. Moor, et al. 2013. Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration. J. Pathol. 229:645–659.
Tögel, F., Z. Hu, K. Weiss, J. Isaac, C. Lange, and C. Westenfelder. 2005. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal Physiol. 289:31–42.
Tögel, F., Y. Yang, P. Zhang, Z. Hu, and C. Westenfelder. 2008. Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am. J. Physiol. Renal Physiol. 295:315–321.
Ward, H. H., E. Romero, A. Welford, G. Pickett, R. Bacallao, V. H. Gattone II, et al. 2011. Adult human CD133/1(+) kidney cells isolated from papilla integrate into developing kidney tubule. Biochim. Biophys. Acta 1812:1344–1357.
Wenger, R. H., and D. Hoogewijs. 2010. Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. Am. J. Physiol. Renal Physiol. 298:F1287–F1296.
Zhuo, W., L. Liao, Y. Fu, T. Xu, W. Wu, S. Yang, et al. 2013. Efficiency of endovenous versus arterial administration of mesenchymal stem cells for ischemia-reperfusion-induced renal dysfunction in rats. Transplant Proc. 45:503–510.
Zou, P., S. Xu, S. P. Povoski, A. Wang, M. A. Johnson, E. W. Martin, Jr., et al. 2009. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol. Pharm. 6:428–440.